Alphanate

Alphanate রক্তক্ষরণ বন্ধকারী (হেমোস্ট্যাটিক) শ্রেণির একটি ওষুধ। মাত্রা, সেবনকাল ও উপযুক্ততা রোগীভেদে আলাদা — তাই রেজিস্টার্ড চিকিৎসকের পরামর্শেই সেবন করুন।

রক্তক্ষরণ বন্ধকারী (হেমোস্ট্যাটিক)

প্রস্তুতকারকের নির্দেশনা অনুযায়ী মাত্রা: • Alphanate contains the labeled amount of Factor VIII expressed in International Units (IU) FVIII/vial and Willebrand. • Factor : Ristocetin Cofactor activity in IU VWF:RCo/vial. • Hemophilia A : Control and prevention of bleeding episodes • Dose (units) = body weight (kg) x desired FVIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL) • Frequency of intravenous injection of the reconstituted product is determined by the type of bleeding episode and the recommendation of the treating physician • Von Willebrand Disease : Surgical and/or invasive procedure in adult and pediatric patients except Type 3 undergoing major surgery • Adults : Pre-operative dose of 60 IU VWF:RCo/kg body weight; subsequent doses of 40-60 IU VWF:RCo/kg/body weight at 8-12 hour intervals post-operative as clinically needed. • Pediatric : Pre-operative dose of 75 IU VWF:RCo/kg/body weight; subsequent doses of 50-75 IU VWF:RCo/kg body weight at 8-12 hour intervals post-operative as clinically needed. • Dosage based on protocol used in the Alphanate prospective clinical trial according to judgment of the investigator. • Pediatric Use - • Hemophilia A Indication : Clinical trials for safety and effectiveness in pediatric hemophilia A patients 16 years of age and younger have not been conducted. • VWD Indication : The hemostatic efficacy of Alphanate has been studied in 20 pediatric subjects with VWD 18 years of age and under. Based on the data from a subset of these subjects, age had no effect on the pharmacokinetics of VWF:RCo. There were no clinically important differences between pediatric patients and adults. • Geriatric Use : No human or animal data. Use only if clearly needed. মাত্রা রোগীর বয়স, ওজন ও অবস্থাভেদে বদলায় — চিকিৎসকের ব্যবস্থাপত্র অনুসরণ করুন।

সেবনবিধি: • Alphanate is for intravenous use only after reconstitution. Use plastic disposable syringes. Do not refrigerate after reconstitution. Reconstituted Alphanate may be stored at room temperature (not to exceed 30° C) prior to administration, but administer intravenously within three hours. • Discard any unused contents into the appropriate safety container. Do not administer Alphanate at a rate exceeding 10 mL/minute.